Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol versus pramipexole for restless legs syndrome
IRCT20210901052359N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of cannabidiol and pramipexole in restless legs syndrome (RLS) (2 arms), sponsored by Iran University of Medical Sciences. Primary endpoint: RLS symptoms. Started Sep 2021; status: completed.
02
Drugs
cannabidiolpramipexole
03
Conditions
restless legs syndrome (RLS)
Beyond the preview
Go deeper on IRCT20210901052359N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210901052359N1.